{"product":"ema-referral-procedure-bodies","name":"EMA human-medicine referral procedure text","free":true,"note":"Count + name + date + status + official PDF URL only. Procedure body is the paid GET /ema-referrals payload. This free manifest lists the full catalog. GET ?id= is one official text for $0.02. Default GET is the newest 10 official texts for $0.05. If the catalog has fewer than 10, that $0.05 GET is the whole current set. Older pages are another $0.05 on the same URL (page/before).","license":"EMA copyright. Public EMA documents may be reproduced for commercial purposes if the European Medicines Agency is acknowledged as the source.","attribution":"European Medicines Agency (EMA)","payTo":"0xf59621FC406D266e18f314Ae18eF0a33b8401004","network":"base","asset":"0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913","amountAtomic":"50000","priceUsdc":"0.05","fetchedAt":"2026-09-05T03:24:58.551Z","asOf":"2026-08-13","cardCount":252,"cards":[{"id":"tavneos","name":"Tavneos","date":"2026-08-13","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/tavneos-article-20-procedure-public-assessment-report_en.pdf","publishedAt":"2026-08-13","page":1,"before":null,"paidUrl":"/ema-referrals?id=tavneos"},{"id":"levamisole-containing-medicinal-products","name":"Levamisole-containing medicinal products","date":"2026-05-13","status":"CMDh final position","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/levamisole-containing-medicinal-products-article-31-referral-assessment-report_en.pdf","publishedAt":"2026-05-13","page":1,"before":null,"paidUrl":"/ema-referrals?id=levamisole-containing-medicinal-products"},{"id":"melatomed-associated-names","name":"Melatomed and associated names","date":"2026-03-17","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/melatomed-article-294-referral-public-assessment-report-including-divergent-positions-chmp-opinion_en.pdf","publishedAt":"2026-03-17","page":1,"before":null,"paidUrl":"/ema-referrals?id=melatomed-associated-names"},{"id":"oxbryta","name":"Oxbryta","date":"2026-01-16","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/oxbryta-article-20-procedure-assessment-report-temporary-measures_en.pdf","publishedAt":"2026-01-16","page":1,"before":null,"paidUrl":"/ema-referrals?id=oxbryta"},{"id":"azithromycin-containing-medicinal-products-systemic-use","name":"Azithromycin-containing medicinal products for systemic use","date":"2025-10-21","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/azithromycin-article-31-referral-assessment-report_en.pdf","publishedAt":"2025-10-21","page":1,"before":null,"paidUrl":"/ema-referrals?id=azithromycin-containing-medicinal-products-systemic-use"},{"id":"finasteride-dutasteride-containing-medicinal-products","name":"Finasteride- and dutasteride-containing medicinal products","date":"2025-09-19","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/finasteride-dutasteride-containing-medicinal-products-article-31-referral-assessment-report_en.pdf","publishedAt":"2025-09-19","page":1,"before":null,"paidUrl":"/ema-referrals?id=finasteride-dutasteride-containing-medicinal-products"},{"id":"mysimba","name":"Mysimba","date":"2025-06-03","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/mysimba-article-20-procedure-assessment-report_en.pdf","publishedAt":"2025-06-03","page":1,"before":null,"paidUrl":"/ema-referrals?id=mysimba"},{"id":"metamizole-containing-medicinal-products-0","name":"Metamizole-containing medicinal products","date":"2025-01-29","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/metamizole-containing-medicinal-products-article-107i-referral-assessment-report_en.pdf","publishedAt":"2025-01-29","page":1,"before":null,"paidUrl":"/ema-referrals?id=metamizole-containing-medicinal-products-0"},{"id":"ocaliva","name":"Ocaliva","date":"2025-01-07","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/ocaliva-article-20-procedure-public-assessment-report_en.pdf","publishedAt":"2025-01-07","page":1,"before":null,"paidUrl":"/ema-referrals?id=ocaliva"},{"id":"lorazepam-macure-4-mg-ml-solution-injection","name":"Lorazepam Macure 4 mg/ml, solution for injection","date":"2024-10-08","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/lorazepam-macure-article-13-referral-assessment-report_en.pdf","publishedAt":"2024-10-08","page":1,"before":null,"paidUrl":"/ema-referrals?id=lorazepam-macure-4-mg-ml-solution-injection"},{"id":"havrix","name":"Havrix","date":"2024-09-04","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/havrix-article-30-referral-assessment-report_en.pdf","publishedAt":"2024-09-04","page":2,"before":"lorazepam-macure-4-mg-ml-solution-injection","paidUrl":"/ema-referrals?id=havrix"},{"id":"hydroxyprogesterone-caproate-containing-medicinal-products","name":"Hydroxyprogesterone caproate-containing medicinal products","date":"2024-07-05","status":"CMDh final position","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/hydroxyprogesterone-containing-medicinal-products-article-31-referral-public-assessment-report_en.pdf","publishedAt":"2024-07-05","page":2,"before":"lorazepam-macure-4-mg-ml-solution-injection","paidUrl":"/ema-referrals?id=hydroxyprogesterone-caproate-containing-medicinal-products"},{"id":"micrazym-associated-names","name":"Micrazym and associated names","date":"2024-06-11","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/micrazym-article-294-referral-assessment-report_en.pdf","publishedAt":"2024-06-11","page":2,"before":"lorazepam-macure-4-mg-ml-solution-injection","paidUrl":"/ema-referrals?id=micrazym-associated-names"},{"id":"synapse","name":"Synapse","date":"2024-06-05","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/synapse-article-31-referral-assessment-report_en.pdf","publishedAt":"2024-06-05","page":2,"before":"lorazepam-macure-4-mg-ml-solution-injection","paidUrl":"/ema-referrals?id=synapse"},{"id":"ibuprofen-nvt","name":"Ibuprofen NVT","date":"2024-06-05","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/ibuprofen-nvt-article-294-referral-assessment-report_en.pdf","publishedAt":"2024-06-05","page":2,"before":"lorazepam-macure-4-mg-ml-solution-injection","paidUrl":"/ema-referrals?id=ibuprofen-nvt"},{"id":"pseudoephedrine-containing-medicinal-products","name":"Pseudoephedrine-containing medicinal products","date":"2024-04-04","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/pseudoephedrine-containing-medicinal-products-article-31-referral-assessment-report_en.pdf","publishedAt":"2024-04-04","page":2,"before":"lorazepam-macure-4-mg-ml-solution-injection","paidUrl":"/ema-referrals?id=pseudoephedrine-containing-medicinal-products"},{"id":"topiramate","name":"Topiramate","date":"2023-11-23","status":"CMDh final position","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/topiramate-article-31-referral-assessment-report_en.pdf","publishedAt":"2023-11-23","page":2,"before":"lorazepam-macure-4-mg-ml-solution-injection","paidUrl":"/ema-referrals?id=topiramate"},{"id":"quinolone-fluoroquinolone-containing-medicinal-products","name":"Quinolone- and fluoroquinolone-containing medicinal products","date":"2023-06-08","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-assessment-report_en.pdf","publishedAt":"2023-06-08","page":2,"before":"lorazepam-macure-4-mg-ml-solution-injection","paidUrl":"/ema-referrals?id=quinolone-fluoroquinolone-containing-medicinal-products"},{"id":"janus-kinase-inhibitors-jaki","name":"Janus kinase inhibitors (JAKi)","date":"2023-05-22","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/janus-kinase-inhibitors-jaki-article-20-procedure-assessment-report_en.pdf","publishedAt":"2023-05-22","page":2,"before":"lorazepam-macure-4-mg-ml-solution-injection","paidUrl":"/ema-referrals?id=janus-kinase-inhibitors-jaki"},{"id":"pholcodine-containing-medicinal-products","name":"Pholcodine-containing medicinal products","date":"2023-03-29","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/pholcodine-containing-medicinal-products-article-107i-referral-assessment-report_en.pdf","publishedAt":"2023-03-29","page":2,"before":"lorazepam-macure-4-mg-ml-solution-injection","paidUrl":"/ema-referrals?id=pholcodine-containing-medicinal-products"},{"id":"gelisia-and-associated-names","name":"Gelisia and associated names","date":"2023-03-16","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/gelisia-article-294-referral-assessment-report_en.pdf","publishedAt":"2023-03-16","page":3,"before":"pholcodine-containing-medicinal-products","paidUrl":"/ema-referrals?id=gelisia-and-associated-names"},{"id":"amfepramone-containing-medicinal-products","name":"Amfepramone-containing medicinal products","date":"2023-01-20","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/amfepramone-containing-medicinal-products-article-31-referral-assessment-report_en.pdf","publishedAt":"2023-01-20","page":3,"before":"pholcodine-containing-medicinal-products","paidUrl":"/ema-referrals?id=amfepramone-containing-medicinal-products"},{"id":"synchron","name":"Synchron","date":"2022-12-16","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/synchron-article-31-referral-assessment-report_en.pdf","publishedAt":"2022-12-16","page":3,"before":"pholcodine-containing-medicinal-products","paidUrl":"/ema-referrals?id=synchron"},{"id":"nomegestrol-chlormadinone","name":"Nomegestrol and chlormadinone","date":"2022-12-14","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/nomegestrol-and-chlormadinone-article-31-referral-assessment-report_en.pdf","publishedAt":"2022-12-14","page":3,"before":"pholcodine-containing-medicinal-products","paidUrl":"/ema-referrals?id=nomegestrol-chlormadinone"},{"id":"terlipressin-containing-medicinal-products-indicated-treatment-hepatorenal-syndrome","name":"Terlipressin-containing medicinal products indicated in the treatment of hepatorenal syndrome","date":"2022-11-22","status":"CMDh final position","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/terlipressin-containing-medicinal-products-article-31-referral-prac-assessment-report_en.pdf","publishedAt":"2022-11-22","page":3,"before":"pholcodine-containing-medicinal-products","paidUrl":"/ema-referrals?id=terlipressin-containing-medicinal-products-indicated-treatment-hepatorenal-syndrome"},{"id":"rubraca","name":"Rubraca","date":"2022-10-17","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/rubraca-article-20-referral-assessment-report-temporary-measures_en.pdf","publishedAt":"2022-10-17","page":3,"before":"pholcodine-containing-medicinal-products","paidUrl":"/ema-referrals?id=rubraca"},{"id":"zynteglo","name":"Zynteglo","date":"2022-07-08","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/zynteglo-article-20-referral-prac-assessment-report_en.pdf","publishedAt":"2022-07-08","page":3,"before":"pholcodine-containing-medicinal-products","paidUrl":"/ema-referrals?id=zynteglo"},{"id":"nasolam-and-associated-names","name":"Nasolam and associated names","date":"2022-04-29","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/nasolam-and-associated-names-article-294-referral-public-assessment-report-including-divergent-positions-chmp-opinion_en.pdf","publishedAt":"2022-04-29","page":3,"before":"pholcodine-containing-medicinal-products","paidUrl":"/ema-referrals?id=nasolam-and-associated-names"},{"id":"lidocain-prilocain-idetec-associated-names","name":"Lidocain/Prilocain Idetec and associated names","date":"2022-04-21","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/lidocainprilocain-idetec-referral-article-294-public-assessment-report-including-divergent-positions-chmp-opinion_en.pdf","publishedAt":"2022-04-21","page":3,"before":"pholcodine-containing-medicinal-products","paidUrl":"/ema-referrals?id=lidocain-prilocain-idetec-associated-names"},{"id":"etifoxine-containing-medicinal-products","name":"Etifoxine-containing medicinal products","date":"2022-04-21","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/etifoxine-containing-medicinal-products-article-31-referral-public-assessment-report-including-divergent-positions-chmp-opinion_en.pdf","publishedAt":"2022-04-21","page":3,"before":"pholcodine-containing-medicinal-products","paidUrl":"/ema-referrals?id=etifoxine-containing-medicinal-products"},{"id":"hydroxyethyl-starch-hes-containing-medicinal-products","name":"Hydroxyethyl starch (HES) containing medicinal products","date":"2022-02-11","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/hydroxyethyl-starch-article-107i-referral-assessment-report_en.pdf","publishedAt":"2022-02-11","page":4,"before":"lidocain-prilocain-idetec-associated-names","paidUrl":"/ema-referrals?id=hydroxyethyl-starch-hes-containing-medicinal-products"},{"id":"intravenous-iron-containing-medicinal-products","name":"Intravenous iron-containing medicinal products","date":"2021-07-28","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-assessment-report_en.pdf","publishedAt":"2021-07-28","page":4,"before":"lidocain-prilocain-idetec-associated-names","paidUrl":"/ema-referrals?id=intravenous-iron-containing-medicinal-products"},{"id":"ifosfamide-solutions","name":"Ifosfamide solutions","date":"2021-07-19","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/ifosfamide-solutions-article-31-referral-assessment-report_en.pdf","publishedAt":"2021-07-19","page":4,"before":"lidocain-prilocain-idetec-associated-names","paidUrl":"/ema-referrals?id=ifosfamide-solutions"},{"id":"varilrix","name":"Varilrix","date":"2021-06-09","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/varilrix-article-30-referral-assessment-report_en.pdf","publishedAt":"2021-06-09","page":4,"before":"lidocain-prilocain-idetec-associated-names","paidUrl":"/ema-referrals?id=varilrix"},{"id":"angiotensin-ii-receptor-antagonists-sartans-containing-tetrazole-group","name":"Angiotensin-II-receptor antagonists (sartans) containing a tetrazole group","date":"2021-03-19","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-chmp-assessment-report-impact-article-53-scientific-opinion-nitrosamines_en.pdf","publishedAt":"2021-03-19","page":4,"before":"lidocain-prilocain-idetec-associated-names","paidUrl":"/ema-referrals?id=angiotensin-ii-receptor-antagonists-sartans-containing-tetrazole-group"},{"id":"ranitidine-containing-medicinal-products","name":"Ranitidine-containing medicinal products","date":"2021-02-17","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/ranitidine-article-31-referral-assessment-report_en.pdf","publishedAt":"2021-02-17","page":4,"before":"lidocain-prilocain-idetec-associated-names","paidUrl":"/ema-referrals?id=ranitidine-containing-medicinal-products"},{"id":"ulipristal-acetate-5mg-medicinal-products","name":"Ulipristal acetate 5mg medicinal products","date":"2021-02-03","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-chmp-scientific-conclusions-and-prac-assessment-report_en.pdf","publishedAt":"2021-02-03","page":4,"before":"lidocain-prilocain-idetec-associated-names","paidUrl":"/ema-referrals?id=ulipristal-acetate-5mg-medicinal-products"},{"id":"ibuprofen-kabi-400-mg-infusionslosung-and-associated-names","name":"Ibuprofen Kabi 400 mg Infusionslösung and associated names","date":"2020-10-26","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/ibuprofen-kabi-400-mg-article-294-referral-assessment-report_en.pdf","publishedAt":"2020-10-26","page":4,"before":"lidocain-prilocain-idetec-associated-names","paidUrl":"/ema-referrals?id=ibuprofen-kabi-400-mg-infusionslosung-and-associated-names"},{"id":"panexcell","name":"Panexcell","date":"2020-10-22","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/panexcell-article-31-referral-assessment-report_en.pdf","publishedAt":"2020-10-22","page":4,"before":"lidocain-prilocain-idetec-associated-names","paidUrl":"/ema-referrals?id=panexcell"},{"id":"budesonide-sun","name":"Budesonide SUN","date":"2020-09-16","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/budesonide-sun-article-294-referral-assessment-report_en.pdf","publishedAt":"2020-09-16","page":4,"before":"lidocain-prilocain-idetec-associated-names","paidUrl":"/ema-referrals?id=budesonide-sun"},{"id":"leuprorelin-containing-depot-medicinal-products","name":"Leuprorelin-containing depot medicinal products","date":"2020-07-31","status":"CMDh final position","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/leuprorelin-containing-depot-medicines-article-31-referral-public-assessment-report-prac-recommendation_en.pdf","publishedAt":"2020-07-31","page":5,"before":"budesonide-sun","paidUrl":"/ema-referrals?id=leuprorelin-containing-depot-medicinal-products"},{"id":"fluorouracil-fluorouracil-related-substances-capecitabine-tegafur-flucytosine-containing-medicinal-products","name":"Fluorouracil and fluorouracil related substances (capecitabine, tegafur and flucytosine) containing medicinal products","date":"2020-07-23","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-assessment-report_en.pdf","publishedAt":"2020-07-23","page":5,"before":"budesonide-sun","paidUrl":"/ema-referrals?id=fluorouracil-fluorouracil-related-substances-capecitabine-tegafur-flucytosine-containing-medicinal-products"},{"id":"carbamazepin-tillomed","name":"Carbamazepin Tillomed","date":"2020-07-21","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/carbamazepin-tillomed-article-294-referral-assessment-report_en.pdf","publishedAt":"2020-07-21","page":5,"before":"budesonide-sun","paidUrl":"/ema-referrals?id=carbamazepin-tillomed"},{"id":"fosfomycin-containing-medicinal-products","name":"Fosfomycin-containing medicinal products","date":"2020-07-06","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/fosfomycin-article-31-referral-assessment-report_en.pdf","publishedAt":"2020-07-06","page":5,"before":"budesonide-sun","paidUrl":"/ema-referrals?id=fosfomycin-containing-medicinal-products"},{"id":"methocarbamol-paracetamol-containing-medicinal-products","name":"Methocarbamol / paracetamol-containing medicinal products","date":"2020-06-17","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/methocarbamol-paracetamol-article-31-referral-assessment-report_en.pdf","publishedAt":"2020-06-17","page":5,"before":"budesonide-sun","paidUrl":"/ema-referrals?id=methocarbamol-paracetamol-containing-medicinal-products"},{"id":"cyproterone-containing-medicinal-products","name":"Cyproterone-containing medicinal products","date":"2020-05-20","status":"CMDh final position","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/cyproterone-article-31-referral-prac-assessment-report_en.pdf","publishedAt":"2020-05-20","page":5,"before":"budesonide-sun","paidUrl":"/ema-referrals?id=cyproterone-containing-medicinal-products"},{"id":"estradiol-containing-001-w-w-medicinal-products-topical-use","name":"Estradiol-containing (0.01% w/w) medicinal products for topical use","date":"2020-04-08","status":"CMDh final position","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/estradiol-containing-001-ww-medicinal-products-topical-use-article-31-referral-prac-assessment-report_en.pdf","publishedAt":"2020-04-08","page":5,"before":"budesonide-sun","paidUrl":"/ema-referrals?id=estradiol-containing-001-w-w-medicinal-products-topical-use"},{"id":"flurbiprofen-geiser","name":"Flurbiprofen Geiser","date":"2020-01-20","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/flurbiprofen-geiser-article-294-referral-assessment-report_en.pdf","publishedAt":"2020-01-20","page":5,"before":"budesonide-sun","paidUrl":"/ema-referrals?id=flurbiprofen-geiser"},{"id":"methotrexate-containing-medicinal-products","name":"Methotrexate containing medicinal products","date":"2019-10-31","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/methotrexate-article-31-referral-public-assessment-report-emeaha-311463_en.pdf","publishedAt":"2019-10-31","page":5,"before":"budesonide-sun","paidUrl":"/ema-referrals?id=methotrexate-containing-medicinal-products"},{"id":"bacterial-lysates-containing-medicinal-products-indicated-respiratory-conditions","name":"Bacterial lysates-containing medicinal products indicated for respiratory conditions","date":"2019-09-16","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/bacterial-lysate-medicines-article-31-referral-chmp-assessment-report_en.pdf","publishedAt":"2019-09-16","page":5,"before":"budesonide-sun","paidUrl":"/ema-referrals?id=bacterial-lysates-containing-medicinal-products-indicated-respiratory-conditions"},{"id":"basiron-ac-associated-names","name":"Basiron AC and associated names","date":"2019-07-19","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/basiron-ac-article-13-referral-assessment-report_en.pdf","publishedAt":"2019-07-19","page":6,"before":"bacterial-lysates-containing-medicinal-products-indicated-respiratory-conditions","paidUrl":"/ema-referrals?id=basiron-ac-associated-names"},{"id":"fenspiride-containing-medicinal-products","name":"Fenspiride containing medicinal products","date":"2019-06-26","status":"CMDh final position","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/fenspiride-containing-medicinal-products-article-107i-referral-assessment-report_en.pdf","publishedAt":"2019-06-26","page":6,"before":"bacterial-lysates-containing-medicinal-products-indicated-respiratory-conditions","paidUrl":"/ema-referrals?id=fenspiride-containing-medicinal-products"},{"id":"septanest-associated-names","name":"Septanest and associated names","date":"2019-06-19","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/septanest-article-30-referral-chmp-assessment-report_en.pdf","publishedAt":"2019-06-19","page":6,"before":"bacterial-lysates-containing-medicinal-products-indicated-respiratory-conditions","paidUrl":"/ema-referrals?id=septanest-associated-names"},{"id":"omega-3-acid-ethyl-esters-containing-medicinal-products-oral-use-secondary-prevention-after-myocardial-infarction","name":"Omega-3 acid ethyl esters - containing medicinal products for oral in use in secondary prevention after myocardial infarction","date":"2019-06-13","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/omega-3-acid-ethyl-esters-assessment-report-following-re-examination-procedure_en.pdf","publishedAt":"2019-06-13","page":6,"before":"bacterial-lysates-containing-medicinal-products-indicated-respiratory-conditions","paidUrl":"/ema-referrals?id=omega-3-acid-ethyl-esters-containing-medicinal-products-oral-use-secondary-prevention-after-myocardial-infarction"},{"id":"syner-kinase-associated-names","name":"Syner-Kinase and associated names","date":"2019-06-03","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/syner-kinase-article-294-referral-chmp-assessment-report_en.pdf","publishedAt":"2019-06-03","page":6,"before":"bacterial-lysates-containing-medicinal-products-indicated-respiratory-conditions","paidUrl":"/ema-referrals?id=syner-kinase-associated-names"},{"id":"metamizole-containing-medicinal-products","name":"Metamizole containing medicinal products","date":"2019-03-28","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/metamizole-article-31-referral-chmp-assessment-report_en.pdf","publishedAt":"2019-03-28","page":6,"before":"bacterial-lysates-containing-medicinal-products-indicated-respiratory-conditions","paidUrl":"/ema-referrals?id=metamizole-containing-medicinal-products"},{"id":"diotop-capsules","name":"Diotop capsules","date":"2019-02-15","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/diotop-article-294-referral-assessment-report_en.pdf","publishedAt":"2019-02-15","page":6,"before":"bacterial-lysates-containing-medicinal-products-indicated-respiratory-conditions","paidUrl":"/ema-referrals?id=diotop-capsules"},{"id":"diclofenac-sodium-spray-gel-4","name":"Diclofenac Sodium Spray Gel 4%","date":"2019-02-14","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/diclofenac-article-294-referral-chmp-assessment-report_en.pdf","publishedAt":"2019-02-14","page":6,"before":"bacterial-lysates-containing-medicinal-products-indicated-respiratory-conditions","paidUrl":"/ema-referrals?id=diclofenac-sodium-spray-gel-4"},{"id":"perlinring-and-associated-names","name":"Perlinring and associated names","date":"2019-01-21","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/perlinring-article-294-referral-assessment-report_en.pdf","publishedAt":"2019-01-21","page":6,"before":"bacterial-lysates-containing-medicinal-products-indicated-respiratory-conditions","paidUrl":"/ema-referrals?id=perlinring-and-associated-names"},{"id":"paclitaxel-hetero-associated-names","name":"Paclitaxel Hetero and associated names","date":"2019-01-21","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/paclitaxel-hetero-and-associated-names-article-294-referral-assessment-report_en.pdf","publishedAt":"2019-01-21","page":6,"before":"bacterial-lysates-containing-medicinal-products-indicated-respiratory-conditions","paidUrl":"/ema-referrals?id=paclitaxel-hetero-associated-names"},{"id":"scandonest-associated-names","name":"Scandonest and associated names","date":"2018-08-07","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/scandonest-article-30-referral-chmp-assessment-report_en.pdf","publishedAt":"2018-08-07","page":7,"before":"perlinring-and-associated-names","paidUrl":"/ema-referrals?id=scandonest-associated-names"},{"id":"zinbryta","name":"Zinbryta","date":"2018-07-11","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/zinbryta-article-20-procedure-assessment-report-provisional-measures_en.pdf","publishedAt":"2018-07-11","page":7,"before":"perlinring-and-associated-names","paidUrl":"/ema-referrals?id=zinbryta"},{"id":"retinoid-containing-medicinal-products","name":"Retinoid-containing medicinal products","date":"2018-07-02","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/retinoid-article-31-referral-prac-assessment-report_en.pdf","publishedAt":"2018-07-02","page":7,"before":"perlinring-and-associated-names","paidUrl":"/ema-referrals?id=retinoid-containing-medicinal-products"},{"id":"valproate-related-substances-0","name":"Valproate and related substances","date":"2018-06-07","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/valproate-article-31-referral-prac-assessment-report_en.pdf","publishedAt":"2018-06-07","page":7,"before":"perlinring-and-associated-names","paidUrl":"/ema-referrals?id=valproate-related-substances-0"},{"id":"flupirtine-containing-medicinal-products","name":"Flupirtine-containing medicinal products","date":"2018-05-04","status":"CMDh final position","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/flupirtine-article-31-referral-assessment-report_en.pdf","publishedAt":"2018-05-04","page":7,"before":"perlinring-and-associated-names","paidUrl":"/ema-referrals?id=flupirtine-containing-medicinal-products"},{"id":"paracetamol-modified-release","name":"Paracetamol modified-release","date":"2018-03-01","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/paracetamol-article-31-referral-prac-assessment-report_en.pdf","publishedAt":"2018-03-01","page":7,"before":"perlinring-and-associated-names","paidUrl":"/ema-referrals?id=paracetamol-modified-release"},{"id":"hydroxyethyl-starch-solutions-infusion","name":"Hydroxyethyl starch solutions for infusion","date":"2018-01-12","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/hydroxyethyl-starch-article-31-referral-prac-assessment-report_en.pdf","publishedAt":"2018-01-12","page":7,"before":"perlinring-and-associated-names","paidUrl":"/ema-referrals?id=hydroxyethyl-starch-solutions-infusion"},{"id":"alcover-associated-names","name":"Alcover and associated names","date":"2018-01-12","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/alcover-article-294-referral-assessment-report_en.pdf","publishedAt":"2018-01-12","page":7,"before":"perlinring-and-associated-names","paidUrl":"/ema-referrals?id=alcover-associated-names"},{"id":"factor-viii","name":"Factor VIII","date":"2017-12-05","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/factor-viii-article-31-referral-assessment-report_en.pdf","publishedAt":"2017-12-05","page":7,"before":"perlinring-and-associated-names","paidUrl":"/ema-referrals?id=factor-viii"},{"id":"gadolinium-containing-contrast-agents","name":"Gadolinium-containing contrast agents","date":"2017-12-04","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/gadolinium-article-31-referral-assessment-report_en.pdf","publishedAt":"2017-12-04","page":7,"before":"perlinring-and-associated-names","paidUrl":"/ema-referrals?id=gadolinium-containing-contrast-agents"},{"id":"vancomycin-containing-medicines","name":"Vancomycin-containing medicines","date":"2017-11-17","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/vancomycin-article-31-referral-assessment-report_en.pdf","publishedAt":"2017-11-17","page":8,"before":"gadolinium-containing-contrast-agents","paidUrl":"/ema-referrals?id=vancomycin-containing-medicines"},{"id":"symbioflor-2","name":"Symbioflor 2","date":"2017-09-07","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/symbioflor-2-article-31-referral-chmp-assessment-report_en.pdf","publishedAt":"2017-09-07","page":8,"before":"gadolinium-containing-contrast-agents","paidUrl":"/ema-referrals?id=symbioflor-2"},{"id":"medicinal-products-containing-lactose-bovine-origin-iv-im-use-acute-allergic-reactions","name":"Medicinal products containing lactose of bovine origin for IV/IM use in acute allergic reactions","date":"2017-09-04","status":"CMDh final position","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/lactose-bovine-origin-article-31-referral-prac-assessment-report_en.pdf","publishedAt":"2017-09-04","page":8,"before":"gadolinium-containing-contrast-agents","paidUrl":"/ema-referrals?id=medicinal-products-containing-lactose-bovine-origin-iv-im-use-acute-allergic-reactions"},{"id":"paracetamol-ibuprofen-500-mg-150-mg-film-coated-tablets","name":"Paracetamol/Ibuprofen 500 mg/150 mg film-coated tablets","date":"2017-08-18","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/paracetamolibuprofen-500mg150mg-article-294-referral-chmp-assessment-report_en.pdf","publishedAt":"2017-08-18","page":8,"before":"gadolinium-containing-contrast-agents","paidUrl":"/ema-referrals?id=paracetamol-ibuprofen-500-mg-150-mg-film-coated-tablets"},{"id":"cardioxane","name":"Cardioxane","date":"2017-07-26","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/cardioxane-article-13-referral-chmp-assessment-report_en.pdf","publishedAt":"2017-07-26","page":8,"before":"gadolinium-containing-contrast-agents","paidUrl":"/ema-referrals?id=cardioxane"},{"id":"vepesid","name":"Vepesid","date":"2017-07-14","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/vepesid-article-30-referral-chmp-assessment-report_en.pdf","publishedAt":"2017-07-14","page":8,"before":"gadolinium-containing-contrast-agents","paidUrl":"/ema-referrals?id=vepesid"},{"id":"etopophos","name":"Etopophos","date":"2017-07-14","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/etopophos-article-30-referral-chmp-assessment-report_en.pdf","publishedAt":"2017-07-14","page":8,"before":"gadolinium-containing-contrast-agents","paidUrl":"/ema-referrals?id=etopophos"},{"id":"micro-therapeutic-research","name":"Micro Therapeutic Research","date":"2017-07-10","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/micro-therapeutic-research-article-31-referral-chmp-assessment-report_en.pdf","publishedAt":"2017-07-10","page":8,"before":"gadolinium-containing-contrast-agents","paidUrl":"/ema-referrals?id=micro-therapeutic-research"},{"id":"saroten-associated-names","name":"Saroten and associated names","date":"2017-06-06","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/saroten-article-30-referral-assessment-report_en.pdf","publishedAt":"2017-06-06","page":8,"before":"gadolinium-containing-contrast-agents","paidUrl":"/ema-referrals?id=saroten-associated-names"},{"id":"haldol-decanoate-associated-names","name":"Haldol Decanoate and associated names","date":"2017-05-11","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/haldol-decanoate-article-30-assessment-report_en.pdf","publishedAt":"2017-05-11","page":8,"before":"gadolinium-containing-contrast-agents","paidUrl":"/ema-referrals?id=haldol-decanoate-associated-names"},{"id":"sglt2-inhibitors-previously-canagliflozin","name":"SGLT2 inhibitors (previously canagliflozin)","date":"2017-05-08","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/sglt2-inhibitors-previously-canagliflozin-article-20-procedure-prac-assessment-report_en.pdf","publishedAt":"2017-05-08","page":9,"before":"haldol-decanoate-associated-names","paidUrl":"/ema-referrals?id=sglt2-inhibitors-previously-canagliflozin"},{"id":"haldol-associated-names","name":"Haldol and associated names","date":"2017-05-05","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/haldol-article-30-referral-assessment-report_en.pdf","publishedAt":"2017-05-05","page":9,"before":"haldol-decanoate-associated-names","paidUrl":"/ema-referrals?id=haldol-associated-names"},{"id":"dienogest-ethinylestradiol-containing-medicinal-products-indicated-acne","name":"Dienogest/ethinylestradiol-containing medicinal products indicated in acne","date":"2017-03-24","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/dienogest-ethinylestradiol-article-31-referral-assessment-report_en.pdf","publishedAt":"2017-03-24","page":9,"before":"haldol-decanoate-associated-names","paidUrl":"/ema-referrals?id=dienogest-ethinylestradiol-containing-medicinal-products-indicated-acne"},{"id":"lovenox-associated-names","name":"Lovenox and associated names","date":"2017-03-22","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/lovenox-article-30-referral-assessment-report_en.pdf","publishedAt":"2017-03-22","page":9,"before":"haldol-decanoate-associated-names","paidUrl":"/ema-referrals?id=lovenox-associated-names"},{"id":"direct-acting-antivirals-indicated-treatment-hepatitis-c-interferon-free","name":"Direct-acting antivirals indicated for treatment of hepatitis C (interferon-free)","date":"2017-03-09","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/direct-acting-antivirals-hepatitis-c-article-20-procedure-prac-assessment-report_en.pdf","publishedAt":"2017-03-09","page":9,"before":"haldol-decanoate-associated-names","paidUrl":"/ema-referrals?id=direct-acting-antivirals-indicated-treatment-hepatitis-c-interferon-free"},{"id":"metformin-metformin-containing-medicines","name":"Metformin and metformin-containing medicines","date":"2016-12-21","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/metformin-article-31-referral-chmp-assessment-report_en.pdf","publishedAt":"2016-12-21","page":9,"before":"haldol-decanoate-associated-names","paidUrl":"/ema-referrals?id=metformin-metformin-containing-medicines"},{"id":"pharmaceutics-international-inc","name":"Pharmaceutics International Inc.","date":"2016-12-14","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/pharmaceutics-international-inc-article-31-referral-chmp-assessment-report_en.pdf","publishedAt":"2016-12-14","page":9,"before":"haldol-decanoate-associated-names","paidUrl":"/ema-referrals?id=pharmaceutics-international-inc"},{"id":"clenil-associated-names","name":"Clenil and associated names","date":"2016-11-18","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/clenil-article-30-referral-chmp-assessment-report_en.pdf","publishedAt":"2016-11-18","page":9,"before":"haldol-decanoate-associated-names","paidUrl":"/ema-referrals?id=clenil-associated-names"},{"id":"semler","name":"Semler","date":"2016-11-17","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/semler-article-31-referral-chmp-assessment-report_en.pdf","publishedAt":"2016-11-17","page":9,"before":"haldol-decanoate-associated-names","paidUrl":"/ema-referrals?id=semler"},{"id":"durogesic-associated-names","name":"Durogesic and associated names","date":"2016-10-19","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/durogesic-article-30-referral-assessment-report_en.pdf","publishedAt":"2016-10-19","page":9,"before":"haldol-decanoate-associated-names","paidUrl":"/ema-referrals?id=durogesic-associated-names"},{"id":"diclofenac-epolamine-50-mg-tablets","name":"Diclofenac epolamine 50 mg tablets","date":"2016-10-10","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/diclofenac-article-29-referral-assessment-report_en.pdf","publishedAt":"2016-10-10","page":10,"before":"durogesic-associated-names","paidUrl":"/ema-referrals?id=diclofenac-epolamine-50-mg-tablets"},{"id":"alkem","name":"Alkem","date":"2016-10-07","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/alkem-article-31-referral-assessment-report_en.pdf","publishedAt":"2016-10-07","page":10,"before":"durogesic-associated-names","paidUrl":"/ema-referrals?id=alkem"},{"id":"zydelig","name":"Zydelig","date":"2016-10-03","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/zydelig-article-20-procedure-assessment-report-provisional-measures_en.pdf","publishedAt":"2016-10-03","page":10,"before":"durogesic-associated-names","paidUrl":"/ema-referrals?id=zydelig"},{"id":"levonelle-1500-microgram-tablets-associated-names","name":"Levonelle 1500 microgram tablets and associated names","date":"2016-08-09","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/levonelle-article-13-referral-chmp-assessment-report_en.pdf","publishedAt":"2016-08-09","page":10,"before":"durogesic-associated-names","paidUrl":"/ema-referrals?id=levonelle-1500-microgram-tablets-associated-names"},{"id":"inhaled-corticosteroids-containing-medicinal-products-indicated-treatment-chronic-obstructive-pulmonary-disease","name":"Inhaled corticosteroids containing medicinal products indicated in the treatment of chronic obstructive pulmonary disease","date":"2016-07-15","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/inhaled-corticosteroids-article-31-referral-prac-assessment-report_en.pdf","publishedAt":"2016-07-15","page":10,"before":"durogesic-associated-names","paidUrl":"/ema-referrals?id=inhaled-corticosteroids-containing-medicinal-products-indicated-treatment-chronic-obstructive-pulmonary-disease"},{"id":"novantrone-associated-names","name":"Novantrone and associated names","date":"2016-07-05","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/novantrone-and-associated-names-article-30-referral-assessment-report_en.pdf","publishedAt":"2016-07-05","page":10,"before":"durogesic-associated-names","paidUrl":"/ema-referrals?id=novantrone-associated-names"},{"id":"cymevene","name":"Cymevene","date":"2016-06-21","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/cymevene-article-30-referral-assessment-report_en.pdf","publishedAt":"2016-06-21","page":10,"before":"durogesic-associated-names","paidUrl":"/ema-referrals?id=cymevene"},{"id":"amoxil","name":"Amoxil","date":"2016-05-19","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/amoxil-article-30-referral-assessment-report_en.pdf","publishedAt":"2016-05-19","page":10,"before":"durogesic-associated-names","paidUrl":"/ema-referrals?id=amoxil"},{"id":"sglt2-inhibitors","name":"SGLT2 inhibitors","date":"2016-05-18","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/sglt2-inhibitors-article-20-procedure-assessment-report_en.pdf","publishedAt":"2016-05-18","page":10,"before":"durogesic-associated-names","paidUrl":"/ema-referrals?id=sglt2-inhibitors"},{"id":"tysabri","name":"Tysabri","date":"2016-05-12","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/tysabri-article-20-procedure-assessment-report_en.pdf","publishedAt":"2016-05-12","page":10,"before":"durogesic-associated-names","paidUrl":"/ema-referrals?id=tysabri"},{"id":"tobramycin-vvb-associated-names","name":"Tobramycin VVB and associated names","date":"2016-05-04","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/tobramycin-vvb-and-associated-names-article-294-referral-chmp-assessment-report_en.pdf","publishedAt":"2016-05-04","page":11,"before":"tysabri","paidUrl":"/ema-referrals?id=tobramycin-vvb-associated-names"},{"id":"fusafungine-containing-medicinal-products-oromucosal-nasal-use","name":"Fusafungine containing medicinal products for oromucosal and nasal use","date":"2016-04-14","status":"CMDh final position","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/fusafungine-article-31-referral-assessment-report_en.pdf","publishedAt":"2016-04-14","page":11,"before":"tysabri","paidUrl":"/ema-referrals?id=fusafungine-containing-medicinal-products-oromucosal-nasal-use"},{"id":"ambroxol-bromhexine-containing-medicines","name":"Ambroxol and bromhexine-containing medicines","date":"2016-02-05","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/ambroxol-and-bromhexine-article-31-referral-prac-assessment-report_en.pdf","publishedAt":"2016-02-05","page":11,"before":"tysabri","paidUrl":"/ema-referrals?id=ambroxol-bromhexine-containing-medicines"},{"id":"human-papillomavirus-vaccines-cervarix-gardasil-gardasil-9-silgard","name":"Human papillomavirus vaccines - Cervarix, Gardasil, Gardasil 9, Silgard","date":"2016-01-20","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/hpv-vaccines-article-20-procedure-assessment-report_en.pdf","publishedAt":"2016-01-20","page":11,"before":"tysabri","paidUrl":"/ema-referrals?id=human-papillomavirus-vaccines-cervarix-gardasil-gardasil-9-silgard"},{"id":"inductos","name":"Inductos","date":"2015-12-07","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/inductos-article-20-procedure-assessment-report_en.pdf","publishedAt":"2015-12-07","page":11,"before":"tysabri","paidUrl":"/ema-referrals?id=inductos"},{"id":"adrenaline-auto-injectors","name":"Adrenaline auto-injectors","date":"2015-08-26","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/adrenaline-auto-injectors-article-31-referral-chmp-assessment-report_en.pdf","publishedAt":"2015-08-26","page":11,"before":"tysabri","paidUrl":"/ema-referrals?id=adrenaline-auto-injectors"},{"id":"gvk-biosciences","name":"GVK Biosciences","date":"2015-08-04","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/gvk-biosciences-article-31-referral-gvk-biosciences-final-assessment-report-following-re-examination-procedure_en.pdf","publishedAt":"2015-08-04","page":11,"before":"tysabri","paidUrl":"/ema-referrals?id=gvk-biosciences"},{"id":"myoson-associated-names","name":"Myoson and associated names","date":"2015-07-28","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/myoson-and-associated-names-article-294-referral-assessment-report_en.pdf","publishedAt":"2015-07-28","page":11,"before":"tysabri","paidUrl":"/ema-referrals?id=myoson-associated-names"},{"id":"merisone-associated-names","name":"Merisone and associated names","date":"2015-07-28","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/merisone-and-associated-names-article-294-referral-assessment-report_en.pdf","publishedAt":"2015-07-28","page":11,"before":"tysabri","paidUrl":"/ema-referrals?id=merisone-associated-names"},{"id":"ibuprofen-dexibuprofen-containing-medicines","name":"Ibuprofen- and dexibuprofen-containing medicines","date":"2015-07-14","status":"CMDh final position","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/ibuprofen-and-dexibuprofen-article-31-referral-assessment-report_en.pdf","publishedAt":"2015-07-14","page":11,"before":"tysabri","paidUrl":"/ema-referrals?id=ibuprofen-dexibuprofen-containing-medicines"},{"id":"ikorel-dancor","name":"Ikorel and Dancor","date":"2015-06-30","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/ikorel-and-dancor-article-30-referral-assessment-report_en.pdf","publishedAt":"2015-06-30","page":12,"before":"ibuprofen-dexibuprofen-containing-medicines","paidUrl":"/ema-referrals?id=ikorel-dancor"},{"id":"hydroxyzine","name":"Hydroxyzine","date":"2015-06-08","status":"CMDh final position","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/hydroxyzine-article-31-referral-prac-assessment-report_en.pdf","publishedAt":"2015-06-08","page":12,"before":"ibuprofen-dexibuprofen-containing-medicines","paidUrl":"/ema-referrals?id=hydroxyzine"},{"id":"plendil-associated-names","name":"Plendil and associated names","date":"2015-03-30","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/plendil-article-30-referral-assessment-report_en.pdf","publishedAt":"2015-03-30","page":12,"before":"ibuprofen-dexibuprofen-containing-medicines","paidUrl":"/ema-referrals?id=plendil-associated-names"},{"id":"nasonex","name":"Nasonex","date":"2015-02-03","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/nasonex-article-30-referral-assessment-report_en.pdf","publishedAt":"2015-02-03","page":12,"before":"ibuprofen-dexibuprofen-containing-medicines","paidUrl":"/ema-referrals?id=nasonex"},{"id":"valproate-related-substances","name":"Valproate and related substances","date":"2015-01-29","status":"CMDh final position","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/valproate-and-related-substances-article-31-referral-prac-assessment-report_en.pdf","publishedAt":"2015-01-29","page":12,"before":"ibuprofen-dexibuprofen-containing-medicines","paidUrl":"/ema-referrals?id=valproate-related-substances"},{"id":"seasonique-associated-names","name":"Seasonique and associated names","date":"2015-01-29","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/seasonique-article-294-referral-assessment-report_en.pdf","publishedAt":"2015-01-29","page":12,"before":"ibuprofen-dexibuprofen-containing-medicines","paidUrl":"/ema-referrals?id=seasonique-associated-names"},{"id":"emla-cream-associated-names","name":"EMLA cream and associated names","date":"2015-01-15","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/emla-cream-article-30-referral-assessment-report_en.pdf","publishedAt":"2015-01-15","page":12,"before":"ibuprofen-dexibuprofen-containing-medicines","paidUrl":"/ema-referrals?id=emla-cream-associated-names"},{"id":"testosterone-containing-medicines","name":"Testosterone-containing medicines","date":"2015-01-08","status":"CMDh final position","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/testosterone-article-31-referral-prac-assessment-report_en.pdf","publishedAt":"2015-01-08","page":12,"before":"ibuprofen-dexibuprofen-containing-medicines","paidUrl":"/ema-referrals?id=testosterone-containing-medicines"},{"id":"polymyxin-containing-medicines","name":"Polymyxin-containing medicines","date":"2015-01-05","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/polymyxin-article-31-referral-assessment-report_en.pdf","publishedAt":"2015-01-05","page":12,"before":"ibuprofen-dexibuprofen-containing-medicines","paidUrl":"/ema-referrals?id=polymyxin-containing-medicines"},{"id":"bromocriptine-containing-medicines-indicated-prevention-or-suppression-physiological-lactation-post-partum","name":"Bromocriptine-containing medicines indicated in the prevention or suppression of physiological lactation post-partum","date":"2014-12-08","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/bromocriptine-article-31-referral-prac-assessment-report_en.pdf","publishedAt":"2014-12-08","page":12,"before":"ibuprofen-dexibuprofen-containing-medicines","paidUrl":"/ema-referrals?id=bromocriptine-containing-medicines-indicated-prevention-or-suppression-physiological-lactation-post-partum"},{"id":"emergency-contraceptives","name":"Emergency contraceptives","date":"2014-10-24","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/emergency-contraceptives-article-31-referral-chmp-assessment-report_en.pdf","publishedAt":"2014-10-24","page":13,"before":"bromocriptine-containing-medicines-indicated-prevention-or-suppression-physiological-lactation-post-partum","paidUrl":"/ema-referrals?id=emergency-contraceptives"},{"id":"renin-angiotensin-system-ras-acting-agents","name":"Renin-angiotensin-system (RAS)-acting agents","date":"2014-10-08","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/renin-angiotensin-system-ras-acting-agents-article-31-referral-assessment-report_en.pdf","publishedAt":"2014-10-08","page":13,"before":"bromocriptine-containing-medicines-indicated-prevention-or-suppression-physiological-lactation-post-partum","paidUrl":"/ema-referrals?id=renin-angiotensin-system-ras-acting-agents"},{"id":"diacerein-containing-medicines-oral-administration","name":"Diacerein-containing medicines for oral administration","date":"2014-09-19","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/diacerein-article-31-referral-prac-assessment-report_en.pdf","publishedAt":"2014-09-19","page":13,"before":"bromocriptine-containing-medicines-indicated-prevention-or-suppression-physiological-lactation-post-partum","paidUrl":"/ema-referrals?id=diacerein-containing-medicines-oral-administration"},{"id":"protelos-osseor","name":"Protelos and Osseor","date":"2014-09-18","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/protelos-and-osseor-article-20-procedure-chmp-scientific-conclusions-and-prac-assessment-report_en.pdf","publishedAt":"2014-09-18","page":13,"before":"bromocriptine-containing-medicines-indicated-prevention-or-suppression-physiological-lactation-post-partum","paidUrl":"/ema-referrals?id=protelos-osseor"},{"id":"linoladiol-n-linoladiol-hn","name":"Linoladiol N and Linoladiol HN","date":"2014-09-11","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/linoladiol-n-and-linoladiol-hn-article-31-referral-chmp-assessment-report_en.pdf","publishedAt":"2014-09-11","page":13,"before":"bromocriptine-containing-medicines-indicated-prevention-or-suppression-physiological-lactation-post-partum","paidUrl":"/ema-referrals?id=linoladiol-n-linoladiol-hn"},{"id":"domperidone-containing-medicines","name":"Domperidone-containing medicines","date":"2014-09-11","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/domperidone-article-31-referral-prac-assessment-report_en.pdf","publishedAt":"2014-09-11","page":13,"before":"bromocriptine-containing-medicines-indicated-prevention-or-suppression-physiological-lactation-post-partum","paidUrl":"/ema-referrals?id=domperidone-containing-medicines"},{"id":"seroquel-seroquel-xr-associated-names","name":"Seroquel / Seroquel XR and associated names","date":"2014-09-09","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/seroquel-seroquel-xr-and-associated-names-article-30-referral-assessment-report_en.pdf","publishedAt":"2014-09-09","page":13,"before":"bromocriptine-containing-medicines-indicated-prevention-or-suppression-physiological-lactation-post-partum","paidUrl":"/ema-referrals?id=seroquel-seroquel-xr-associated-names"},{"id":"dexamed-associated-names","name":"Dexamed and associated names","date":"2014-09-02","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/dexamed-and-associated-names-article-294-referral-assessment-report_en.pdf","publishedAt":"2014-09-02","page":13,"before":"bromocriptine-containing-medicines-indicated-prevention-or-suppression-physiological-lactation-post-partum","paidUrl":"/ema-referrals?id=dexamed-associated-names"},{"id":"caustinerf-arsenical-yranicid-arsenical","name":"Caustinerf arsenical and Yranicid arsenical","date":"2014-08-06","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/caustinerf-arsenical-and-yranicid-arsenical-article-31-referral-chmp-assessment-report_en.pdf","publishedAt":"2014-08-06","page":13,"before":"bromocriptine-containing-medicines-indicated-prevention-or-suppression-physiological-lactation-post-partum","paidUrl":"/ema-referrals?id=caustinerf-arsenical-yranicid-arsenical"},{"id":"zolpidem-containing-medicines","name":"Zolpidem-containing medicines","date":"2014-08-04","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/zolpidem-article-31-referral-prac-assessment-report_en.pdf","publishedAt":"2014-08-04","page":14,"before":"methadone-medicinal-products-oral-use-containing-povidone","paidUrl":"/ema-referrals?id=zolpidem-containing-medicines"},{"id":"methadone-medicinal-products-oral-use-containing-povidone","name":"Methadone medicinal products for oral use containing povidone","date":"2014-08-04","status":"CMDh final position","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/methadone-article-107i-procedure-prac-assessment-report_en.pdf","publishedAt":"2014-08-04","page":13,"before":"bromocriptine-containing-medicines-indicated-prevention-or-suppression-physiological-lactation-post-partum","paidUrl":"/ema-referrals?id=methadone-medicinal-products-oral-use-containing-povidone"},{"id":"nanotop-associated-names","name":"Nanotop and associated names","date":"2014-06-16","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-nanotop-and-associated-names-human-albumin-colloidal-particles-kit-radiopharmaceutical-preparation_en.pdf","publishedAt":"2014-06-16","page":14,"before":"methadone-medicinal-products-oral-use-containing-povidone","paidUrl":"/ema-referrals?id=nanotop-associated-names"},{"id":"ketoconazole-containing-medicines","name":"Ketoconazole-containing medicines","date":"2014-06-13","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/ketoconazole-article-31-referral-assessment-report_en.pdf","publishedAt":"2014-06-13","page":14,"before":"methadone-medicinal-products-oral-use-containing-povidone","paidUrl":"/ema-referrals?id=ketoconazole-containing-medicines"},{"id":"methysergide-containing-medicines","name":"Methysergide-containing medicines","date":"2014-05-27","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/methysergide-article-31-referral-assessment-report_en.pdf","publishedAt":"2014-05-27","page":14,"before":"methadone-medicinal-products-oral-use-containing-povidone","paidUrl":"/ema-referrals?id=methysergide-containing-medicines"},{"id":"rocephin","name":"Rocephin","date":"2014-05-19","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/rocephin-article-30-referral-assessment-report_en.pdf","publishedAt":"2014-05-19","page":14,"before":"methadone-medicinal-products-oral-use-containing-povidone","paidUrl":"/ema-referrals?id=rocephin"},{"id":"tibolona-aristo-tibocina-associated-names","name":"Tibolona Aristo and Tibocina and associated names","date":"2014-04-08","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/tibolona-aristo-and-tibocina-and-associated-names-article-294-referral-assessment-report_en.pdf","publishedAt":"2014-04-08","page":14,"before":"methadone-medicinal-products-oral-use-containing-povidone","paidUrl":"/ema-referrals?id=tibolona-aristo-tibocina-associated-names"},{"id":"valebo-associated-names","name":"Valebo and associated names","date":"2014-03-31","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/valebo-and-associated-names-article-294-referral-assessment-report_en.pdf","publishedAt":"2014-03-31","page":14,"before":"methadone-medicinal-products-oral-use-containing-povidone","paidUrl":"/ema-referrals?id=valebo-associated-names"},{"id":"valtrex","name":"Valtrex","date":"2014-03-25","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/valtrex-article-30-referral-assessment-report_en.pdf","publishedAt":"2014-03-25","page":14,"before":"methadone-medicinal-products-oral-use-containing-povidone","paidUrl":"/ema-referrals?id=valtrex"},{"id":"substances-related-nicotinic-acid","name":"Substances related to nicotinic acid","date":"2014-03-13","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/substances-related-nicotinic-acid-article-31-referral-assessment-report_en.pdf","publishedAt":"2014-03-13","page":14,"before":"methadone-medicinal-products-oral-use-containing-povidone","paidUrl":"/ema-referrals?id=substances-related-nicotinic-acid"},{"id":"monovalent-multivalent-measles-mumps-rubella-or-varicella-vaccines","name":"Monovalent and multivalent measles, mumps, rubella and / or varicella vaccines","date":"2014-03-12","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/monovalent-and-multivalent-measles-mumps-rubella-and-or-varicella-vaccines-article-31-referral-assessment-report_en.pdf","publishedAt":"2014-03-12","page":15,"before":"intravenous-nicardipine-medicines","paidUrl":"/ema-referrals?id=monovalent-multivalent-measles-mumps-rubella-or-varicella-vaccines"},{"id":"intravenous-nicardipine-medicines","name":"Intravenous nicardipine medicines","date":"2014-03-12","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/nicardipine-article-31-referral-assessment-report_en.pdf","publishedAt":"2014-03-12","page":14,"before":"methadone-medicinal-products-oral-use-containing-povidone","paidUrl":"/ema-referrals?id=intravenous-nicardipine-medicines"},{"id":"thiocolchicoside-containing-medicines","name":"Thiocolchicoside-containing medicines","date":"2014-03-06","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/thiocolchicoside-article-31-referral-assessment-report_en.pdf","publishedAt":"2014-03-06","page":15,"before":"intravenous-nicardipine-medicines","paidUrl":"/ema-referrals?id=thiocolchicoside-containing-medicines"},{"id":"hydroxyethyl-starch-solutions-infusion-0","name":"Hydroxyethyl starch solutions for infusion","date":"2014-03-06","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/hydroxyethyl-starch-article-107i-procedure-prac-assessment-report_en.pdf","publishedAt":"2014-03-06","page":15,"before":"intravenous-nicardipine-medicines","paidUrl":"/ema-referrals?id=hydroxyethyl-starch-solutions-infusion-0"},{"id":"ergot-derivatives","name":"Ergot derivatives","date":"2014-02-17","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/assessment-report-ergot-derivatives-containing-medicinal-products-dihydroergocristine_en.pdf","publishedAt":"2014-02-17","page":15,"before":"intravenous-nicardipine-medicines","paidUrl":"/ema-referrals?id=ergot-derivatives"},{"id":"metoclopramide-containing-medicines","name":"Metoclopramide-containing medicines","date":"2014-02-06","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/assessment-report-metoclopramide-containing-medicines_en.pdf","publishedAt":"2014-02-06","page":15,"before":"intravenous-nicardipine-medicines","paidUrl":"/ema-referrals?id=metoclopramide-containing-medicines"},{"id":"combined-hormonal-contraceptives","name":"Combined hormonal contraceptives","date":"2014-01-31","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/combined-hormonal-contraceptives-article-31-referral-prac-assessment-report_en.pdf","publishedAt":"2014-01-31","page":15,"before":"intravenous-nicardipine-medicines","paidUrl":"/ema-referrals?id=combined-hormonal-contraceptives"},{"id":"targocid-associated-names","name":"Targocid and associated names","date":"2014-01-03","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/targocid-article-30-referral-chmp-assessment-report_en.pdf","publishedAt":"2014-01-03","page":15,"before":"intravenous-nicardipine-medicines","paidUrl":"/ema-referrals?id=targocid-associated-names"},{"id":"okrido","name":"Okrido","date":"2014-01-03","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/okrido-article-29-referral-chmp-assessment-report_en.pdf","publishedAt":"2014-01-03","page":15,"before":"intravenous-nicardipine-medicines","paidUrl":"/ema-referrals?id=okrido"},{"id":"sandimmun-neoral-associated-names","name":"Sandimmun Neoral and associated names","date":"2013-12-20","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/sandimmun-neoral-article-30-referral-assessment-report_en.pdf","publishedAt":"2013-12-20","page":15,"before":"intravenous-nicardipine-medicines","paidUrl":"/ema-referrals?id=sandimmun-neoral-associated-names"},{"id":"sandimmun-associated-names","name":"Sandimmun and associated names","date":"2013-12-20","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/sandimmun-article-30-referral-assessment-report_en.pdf","publishedAt":"2013-12-20","page":15,"before":"intravenous-nicardipine-medicines","paidUrl":"/ema-referrals?id=sandimmun-associated-names"},{"id":"didanosine","name":"Didanosine","date":"2013-12-10","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/didanosine-article-29-referral-assessment-report_en.pdf","publishedAt":"2013-12-10","page":16,"before":"sandimmun-neoral-associated-names","paidUrl":"/ema-referrals?id=didanosine"},{"id":"methylphenidate-sandoz","name":"Methylphenidate Sandoz","date":"2013-12-05","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/methylphenidate-sandoz-article-29-referral-assessment-report_en.pdf","publishedAt":"2013-12-05","page":16,"before":"sandimmun-neoral-associated-names","paidUrl":"/ema-referrals?id=methylphenidate-sandoz"},{"id":"methylphenidate-hexal","name":"Methylphenidate Hexal","date":"2013-12-05","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/methylphenidate-hexal-article-29-referral-assessment-report_en.pdf","publishedAt":"2013-12-05","page":16,"before":"sandimmun-neoral-associated-names","paidUrl":"/ema-referrals?id=methylphenidate-hexal"},{"id":"diclofenac-containing-medicines","name":"Diclofenac-containing medicines","date":"2013-11-27","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/diclofenac-article-31-referral-prac-assessment-report_en.pdf","publishedAt":"2013-11-27","page":16,"before":"sandimmun-neoral-associated-names","paidUrl":"/ema-referrals?id=diclofenac-containing-medicines"},{"id":"flupirtine-containing-medicines","name":"Flupirtine-containing medicines","date":"2013-11-21","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/flupirtine-containing-medicines-article-107i-procedure-prac-assessment-report_en.pdf","publishedAt":"2013-11-21","page":16,"before":"sandimmun-neoral-associated-names","paidUrl":"/ema-referrals?id=flupirtine-containing-medicines"},{"id":"ciclosporin-idl","name":"Ciclosporin IDL","date":"2013-11-20","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-referral-ciclosporin-idl-and-associated-names-capsules-containing-ciclosporin-25-mg-50-mg-and-100-mg-re-examination_en.pdf","publishedAt":"2013-11-20","page":16,"before":"sandimmun-neoral-associated-names","paidUrl":"/ema-referrals?id=ciclosporin-idl"},{"id":"tazocin","name":"Tazocin","date":"2013-11-19","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/tazocin-article-30-referral-assessment-report_en.pdf","publishedAt":"2013-11-19","page":16,"before":"sandimmun-neoral-associated-names","paidUrl":"/ema-referrals?id=tazocin"},{"id":"avalox","name":"Avalox","date":"2013-11-19","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-referral-avalox-solution-infusion-containing-moxifloxacin-400-mg250-ml_en.pdf","publishedAt":"2013-11-19","page":16,"before":"sandimmun-neoral-associated-names","paidUrl":"/ema-referrals?id=avalox"},{"id":"augmentin","name":"Augmentin","date":"2013-11-18","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-referral-augmentin-amoxicillin-and-clavulanic-acid_en.pdf","publishedAt":"2013-11-18","page":16,"before":"sandimmun-neoral-associated-names","paidUrl":"/ema-referrals?id=augmentin"},{"id":"short-acting-beta-agonists","name":"Short-acting beta-agonists","date":"2013-11-07","status":"CMDh final position","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/short-acting-beta-agonists-article-31-referral-prac-assessment-report_en.pdf","publishedAt":"2013-11-07","page":16,"before":"sandimmun-neoral-associated-names","paidUrl":"/ema-referrals?id=short-acting-beta-agonists"},{"id":"antifibrinolytic-medicines","name":"Antifibrinolytic medicines","date":"2013-11-06","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/assessment-report-antifibrinolytic-medicines-aprotinin_en.pdf","publishedAt":"2013-11-06","page":17,"before":"short-acting-beta-agonists","paidUrl":"/ema-referrals?id=antifibrinolytic-medicines"},{"id":"numeta-g13e-numeta-g16e-emulsion-infusion","name":"Numeta G13%E and Numeta G16%E emulsion for infusion","date":"2013-09-27","status":"CMDh final position","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/numeta-article-107i-procedure-prac-assessment-report_en.pdf","publishedAt":"2013-09-27","page":17,"before":"short-acting-beta-agonists","paidUrl":"/ema-referrals?id=numeta-g13e-numeta-g16e-emulsion-infusion"},{"id":"cilostazol-containing-medicines","name":"Cilostazol-containing medicines","date":"2013-09-11","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/assessment-report-cilostazol-containing-medicinal-products_en.pdf","publishedAt":"2013-09-11","page":17,"before":"short-acting-beta-agonists","paidUrl":"/ema-referrals?id=cilostazol-containing-medicines"},{"id":"cyproterone-ethinylestradiol-containing-medicines","name":"Cyproterone- and ethinylestradiol-containing medicines","date":"2013-08-05","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/cyproterone-ethinylestradiol-containing-medicines-article-107i-procedure-prac-assessment-report_en.pdf","publishedAt":"2013-08-05","page":17,"before":"short-acting-beta-agonists","paidUrl":"/ema-referrals?id=cyproterone-ethinylestradiol-containing-medicines"},{"id":"codeine-containing-medicines","name":"Codeine-containing medicines","date":"2013-08-02","status":"CMDh final position","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/codeine-article-31-referral-prac-assessment-report_en.pdf","publishedAt":"2013-08-02","page":17,"before":"short-acting-beta-agonists","paidUrl":"/ema-referrals?id=codeine-containing-medicines"},{"id":"furosemide-vitabalans","name":"Furosemide Vitabalans","date":"2013-07-30","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/furosemide-vitabalans-article-294-referral-assessment-report_en.pdf","publishedAt":"2013-07-30","page":17,"before":"short-acting-beta-agonists","paidUrl":"/ema-referrals?id=furosemide-vitabalans"},{"id":"simvastatin-vale","name":"Simvastatin Vale","date":"2013-07-22","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/assessment-report-simvastatin-vale-and-associated-names_en.pdf","publishedAt":"2013-07-22","page":17,"before":"short-acting-beta-agonists","paidUrl":"/ema-referrals?id=simvastatin-vale"},{"id":"calcitonin","name":"Calcitonin","date":"2013-07-19","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/assessment-report-calcitonin-containing-medicinal-products_en.pdf","publishedAt":"2013-07-19","page":17,"before":"short-acting-beta-agonists","paidUrl":"/ema-referrals?id=calcitonin"},{"id":"tetrazepam-containing-medicines","name":"Tetrazepam-containing medicines","date":"2013-07-18","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/tetrazepam-containing-medicines-article-107i-procedure-prac-assessment-report_en.pdf","publishedAt":"2013-07-18","page":17,"before":"short-acting-beta-agonists","paidUrl":"/ema-referrals?id=tetrazepam-containing-medicines"},{"id":"fibrates","name":"Fibrates","date":"2013-04-03","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/assessment-report-fenofibrate-bezafibrate-ciprofibrate-and-gemfibrozil-containing-medicinal-products_en.pdf","publishedAt":"2013-04-03","page":17,"before":"short-acting-beta-agonists","paidUrl":"/ema-referrals?id=fibrates"},{"id":"tolperisone","name":"Tolperisone","date":"2013-04-02","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/assessment-report-tolperisone-containing-medicinal-products_en.pdf","publishedAt":"2013-04-02","page":18,"before":"fibrates","paidUrl":"/ema-referrals?id=tolperisone"},{"id":"fibrinogen-containing-solutions-sealant-authorised-administration-spray-application-0","name":"Fibrinogen-containing solutions for sealant authorised for administration by spray application","date":"2013-04-02","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/assessment-report-fibrinogen-containing-solutions-sealant-authorised-administration-spray-application_en.pdf","publishedAt":"2013-04-02","page":18,"before":"fibrates","paidUrl":"/ema-referrals?id=fibrinogen-containing-solutions-sealant-authorised-administration-spray-application-0"},{"id":"fibrinogen-containing-solutions-sealant-authorised-administration-spray-application","name":"Fibrinogen-containing solutions for sealant authorised for administration by spray application","date":"2013-04-02","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/assessment-report-fibrinogen-containing-solutions-sealant-authorised-administration-spray-application-tisseel-tissucol-artiss-beriplast-p-and-associated-names_en.pdf","publishedAt":"2013-04-02","page":18,"before":"fibrates","paidUrl":"/ema-referrals?id=fibrinogen-containing-solutions-sealant-authorised-administration-spray-application"},{"id":"medicines-studied-cetero-research-facility","name":"Medicines studied at Cetero Research facility","date":"2013-03-12","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/assessment-report-cilazapril-teva_en.pdf","publishedAt":"2013-03-12","page":18,"before":"fibrates","paidUrl":"/ema-referrals?id=medicines-studied-cetero-research-facility"},{"id":"loraxin","name":"Loraxin","date":"2013-02-28","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/loraxin-article-294-referral-assessment-report_en.pdf","publishedAt":"2013-02-28","page":18,"before":"fibrates","paidUrl":"/ema-referrals?id=loraxin"},{"id":"zinacef","name":"Zinacef","date":"2013-01-29","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/assessment-report-zinacef-and-associated-names_en.pdf","publishedAt":"2013-01-29","page":18,"before":"fibrates","paidUrl":"/ema-referrals?id=zinacef"},{"id":"mometasone-furoate-sandoz","name":"Mometasone Furoate Sandoz","date":"2013-01-24","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/mometasone-furoate-sandoz-article-294-referral-assessment-report_en.pdf","publishedAt":"2013-01-24","page":18,"before":"fibrates","paidUrl":"/ema-referrals?id=mometasone-furoate-sandoz"},{"id":"yaz-244","name":"Yaz 24+4","date":"2013-01-11","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/ethinylestradiol-drospirenone-244-article-612-referral-assessment-report_en.pdf","publishedAt":"2013-01-11","page":18,"before":"fibrates","paidUrl":"/ema-referrals?id=yaz-244"},{"id":"ethinylestradiol-drospirenone-244","name":"Ethinylestradiol-Drospirenone 24+4","date":"2013-01-11","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/ethinylestradiol-drospirenone-244-article-612-referral-assessment-report_en.pdf","publishedAt":"2013-01-11","page":18,"before":"fibrates","paidUrl":"/ema-referrals?id=ethinylestradiol-drospirenone-244"},{"id":"yvidually","name":"Yvidually","date":"2013-01-03","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/yvidually-article-294-referral-assessment-report_en.pdf","publishedAt":"2013-01-03","page":19,"before":"mifepristone-linepharma","paidUrl":"/ema-referrals?id=yvidually"},{"id":"mifepristone-linepharma","name":"Mifepristone Linepharma","date":"2013-01-03","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/mifepristone-article-294-referral-assessment-report_en.pdf","publishedAt":"2013-01-03","page":18,"before":"fibrates","paidUrl":"/ema-referrals?id=mifepristone-linepharma"},{"id":"orlistat","name":"Orlistat","date":"2012-12-21","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/orlistat-article-31-referral-assessment-report-orlistat-containing-medicinal-products_en.pdf","publishedAt":"2012-12-21","page":19,"before":"mifepristone-linepharma","paidUrl":"/ema-referrals?id=orlistat"},{"id":"glimepirida-parke-davis","name":"Glimepirida Parke-Davis","date":"2012-12-06","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/glimepirida-parke-davis-article-294-referral-assessment-report_en.pdf","publishedAt":"2012-12-06","page":19,"before":"mifepristone-linepharma","paidUrl":"/ema-referrals?id=glimepirida-parke-davis"},{"id":"iffeza","name":"Iffeza","date":"2012-10-25","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/iffeza-article-29-referral-assessment-report_en.pdf","publishedAt":"2012-10-25","page":19,"before":"mifepristone-linepharma","paidUrl":"/ema-referrals?id=iffeza"},{"id":"flutiform","name":"Flutiform","date":"2012-10-25","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/flutiform-article-29-referral-assessment-report_en.pdf","publishedAt":"2012-10-25","page":19,"before":"mifepristone-linepharma","paidUrl":"/ema-referrals?id=flutiform"},{"id":"trimetazidine","name":"Trimetazidine","date":"2012-10-17","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/trimetazidine-article-31-referral-assessment-report_en.pdf","publishedAt":"2012-10-17","page":19,"before":"mifepristone-linepharma","paidUrl":"/ema-referrals?id=trimetazidine"},{"id":"tavanic","name":"Tavanic","date":"2012-09-12","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/tavanic-article-30-referral-assessment-report_en.pdf","publishedAt":"2012-09-12","page":19,"before":"mifepristone-linepharma","paidUrl":"/ema-referrals?id=tavanic"},{"id":"valproat-ratiopharm-chrono","name":"Valproat Ratiopharm Chrono","date":"2012-07-23","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-review-medicines-containing-valproate-use-bipolar-disorder_en.pdf","publishedAt":"2012-07-23","page":19,"before":"mifepristone-linepharma","paidUrl":"/ema-referrals?id=valproat-ratiopharm-chrono"},{"id":"docetaxel-teva-generics","name":"Docetaxel Teva Generics","date":"2012-07-03","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/docetaxel-teva-generics-article-29-referral-assessment-report_en.pdf","publishedAt":"2012-07-03","page":19,"before":"mifepristone-linepharma","paidUrl":"/ema-referrals?id=docetaxel-teva-generics"},{"id":"priorix","name":"Priorix","date":"2012-06-19","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/priorix-article-30-referral-assessment-report_en.pdf","publishedAt":"2012-06-19","page":19,"before":"mifepristone-linepharma","paidUrl":"/ema-referrals?id=priorix"},{"id":"buflomedil","name":"Buflomedil","date":"2012-06-13","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/buflomedil-article-107-referral-assessment-report_en.pdf","publishedAt":"2012-06-13","page":20,"before":"priorix","paidUrl":"/ema-referrals?id=buflomedil"},{"id":"femara","name":"Femara","date":"2012-06-12","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/femara-article-30-referral-assessment-report_en.pdf","publishedAt":"2012-06-12","page":20,"before":"priorix","paidUrl":"/ema-referrals?id=femara"},{"id":"meprobamate","name":"Meprobamate","date":"2012-06-08","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/meprobamate-article-107-referral-assessment-report_en.pdf","publishedAt":"2012-06-08","page":20,"before":"priorix","paidUrl":"/ema-referrals?id=meprobamate"},{"id":"galantamine-stada","name":"Galantamine Stada","date":"2012-06-08","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-galantamine-stada-and-associated-names-galantamine-8-16-and-24-mg-prolonged-released-tablets_en.pdf","publishedAt":"2012-06-08","page":20,"before":"priorix","paidUrl":"/ema-referrals?id=galantamine-stada"},{"id":"somatropin","name":"Somatropin","date":"2012-04-23","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/somatropin-article-107-referral-assessment-report_en.pdf","publishedAt":"2012-04-23","page":20,"before":"priorix","paidUrl":"/ema-referrals?id=somatropin"},{"id":"nimesulide-1","name":"Nimesulide","date":"2012-04-19","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/nimesulide-article-31-referral-assessment-report_en.pdf","publishedAt":"2012-04-19","page":20,"before":"priorix","paidUrl":"/ema-referrals?id=nimesulide-1"},{"id":"terpenic-derivatives","name":"Terpenic derivatives","date":"2012-04-13","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/terpenic-derivatives-article-31-referral-assessment-report_en.pdf","publishedAt":"2012-04-13","page":20,"before":"priorix","paidUrl":"/ema-referrals?id=terpenic-derivatives"},{"id":"lipitor","name":"Lipitor","date":"2012-04-10","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-lipitor-and-associated-names-atorvastatin-10-20-40-and-80-mg-tablets_en.pdf","publishedAt":"2012-04-10","page":20,"before":"priorix","paidUrl":"/ema-referrals?id=lipitor"},{"id":"norvasc","name":"Norvasc","date":"2012-03-29","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/norvasc-article-30-referral-assessment-report_en.pdf","publishedAt":"2012-03-29","page":20,"before":"priorix","paidUrl":"/ema-referrals?id=norvasc"},{"id":"priligy","name":"Priligy","date":"2012-03-28","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/priligy-article-29-referral-assessment-report_en.pdf","publishedAt":"2012-03-28","page":21,"before":"pholcodine","paidUrl":"/ema-referrals?id=priligy"},{"id":"pholcodine","name":"Pholcodine","date":"2012-03-28","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/pholcodine-article-31-referral-assessment-report_en.pdf","publishedAt":"2012-03-28","page":20,"before":"priorix","paidUrl":"/ema-referrals?id=pholcodine"},{"id":"tienam","name":"Tienam","date":"2012-02-20","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/assessment-report-tienam-and-associated-names_en.pdf","publishedAt":"2012-02-20","page":21,"before":"pholcodine","paidUrl":"/ema-referrals?id=tienam"},{"id":"canazole","name":"Canazole","date":"2012-02-09","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/canazole-article-29-referral-assessment-report_en.pdf","publishedAt":"2012-02-09","page":21,"before":"pholcodine","paidUrl":"/ema-referrals?id=canazole"},{"id":"diflucan","name":"Diflucan","date":"2012-02-02","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/diflucan-article-30-referral-assessment-report_en.pdf","publishedAt":"2012-02-02","page":21,"before":"pholcodine","paidUrl":"/ema-referrals?id=diflucan"},{"id":"dexamethasone-alapis","name":"Dexamethasone Alapis","date":"2012-02-02","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/dexamethasone-alapis-article-29-referral-assessment-report_en.pdf","publishedAt":"2012-02-02","page":21,"before":"pholcodine","paidUrl":"/ema-referrals?id=dexamethasone-alapis"},{"id":"levothyroxine-alapis","name":"Levothyroxine Alapis","date":"2012-01-19","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/levothyroxine-alapis-article-29-referral-assessment-report_en.pdf","publishedAt":"2012-01-19","page":21,"before":"pholcodine","paidUrl":"/ema-referrals?id=levothyroxine-alapis"},{"id":"protium","name":"Protium","date":"2012-01-17","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-referral-protium-and-associated-names-pantoprazole-20-or-40-mg-gastro-resistant-tablets-and-40-mg-powder-solution-injection_en.pdf","publishedAt":"2012-01-17","page":21,"before":"pholcodine","paidUrl":"/ema-referrals?id=protium"},{"id":"dexrazoxane","name":"Dexrazoxane","date":"2012-01-16","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/dexrazoxane-h-31-1275-article-31-referral-assessment-report_en.pdf","publishedAt":"2012-01-16","page":21,"before":"pholcodine","paidUrl":"/ema-referrals?id=dexrazoxane"},{"id":"cozaar-0","name":"Cozaar","date":"2012-01-13","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/chmp-assessment-report-cozaar-and-associated-names_en.pdf","publishedAt":"2012-01-13","page":21,"before":"pholcodine","paidUrl":"/ema-referrals?id=cozaar-0"},{"id":"vascace-plus","name":"Vascace Plus","date":"2011-11-09","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/vascace-plus-article-30-referral-assessment-report_en.pdf","publishedAt":"2011-11-09","page":21,"before":"pholcodine","paidUrl":"/ema-referrals?id=vascace-plus"},{"id":"ketoprofen-topical","name":"Ketoprofen topical","date":"2011-10-28","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/assessment-report-ketoprofen-containing-medicinal-products-topical-formulations_en.pdf","publishedAt":"2011-10-28","page":22,"before":"vascace-plus","paidUrl":"/ema-referrals?id=ketoprofen-topical"},{"id":"bisphosphonates","name":"Bisphosphonates","date":"2011-10-28","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/assessment-report-bisphosphonates-containing-medicinal-products_en.pdf","publishedAt":"2011-10-28","page":22,"before":"vascace-plus","paidUrl":"/ema-referrals?id=bisphosphonates"},{"id":"atacand-plus","name":"Atacand Plus","date":"2011-09-21","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-atacand-plus-and-associated-names-candesartan-cilexetilhydrochlorothiazide-tablets-8125-mg-16125-mg-32125-mg-and-3225-mg_en.pdf","publishedAt":"2011-09-21","page":22,"before":"vascace-plus","paidUrl":"/ema-referrals?id=atacand-plus"},{"id":"prevora","name":"Prevora","date":"2011-09-20","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-prevora-chlorhexidine-diacetate-100-mgml-dental-solution_en.pdf","publishedAt":"2011-09-20","page":22,"before":"vascace-plus","paidUrl":"/ema-referrals?id=prevora"},{"id":"losec","name":"Losec","date":"2011-09-19","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-losec-and-associated-names-omeprazole-10-20-or-40-mg-capsules-and-tablets-and-40-mg-solution-injection-and-solution-infusion_en.pdf","publishedAt":"2011-09-19","page":22,"before":"vascace-plus","paidUrl":"/ema-referrals?id=losec"},{"id":"norsed-combi-d","name":"Norsed Combi D","date":"2011-09-13","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-norsed-combi-d-and-associated-names-risedronate-sodium-35-mg-tablets-calcium-plus-colecalciferol-1000-mg880-iu-effervescent-granules_en.pdf","publishedAt":"2011-09-13","page":22,"before":"vascace-plus","paidUrl":"/ema-referrals?id=norsed-combi-d"},{"id":"lescol","name":"Lescol","date":"2011-09-13","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-referral-lescol-and-associated-names-capsules-containing-20-mg-or-40-mg-fluvastatin-prolonged-release-tablets-containing-80-mg-fluvastatin_en.pdf","publishedAt":"2011-09-13","page":22,"before":"vascace-plus","paidUrl":"/ema-referrals?id=lescol"},{"id":"fortipan-combi-d","name":"Fortipan Combi D","date":"2011-09-13","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-fortipan-combi-d-and-associated-names-risedronate-sodium-35-mg-tablets-calcium-plus-colecalciferol-1000-mg880-iu-effervescent-granules_en.pdf","publishedAt":"2011-09-13","page":22,"before":"vascace-plus","paidUrl":"/ema-referrals?id=fortipan-combi-d"},{"id":"kytril","name":"Kytril","date":"2011-09-12","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/assessment-report-pursuant-article-30-directive-200183ec-kytril-and-associated-names_en.pdf","publishedAt":"2011-09-12","page":22,"before":"vascace-plus","paidUrl":"/ema-referrals?id=kytril"},{"id":"famvir","name":"Famvir","date":"2011-09-09","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/famvir-article-30-referral-assessment-report_en.pdf","publishedAt":"2011-09-09","page":22,"before":"vascace-plus","paidUrl":"/ema-referrals?id=famvir"},{"id":"levact","name":"Levact","date":"2011-09-08","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-levact-and-associated-names-bendamustine-hydrochloride-25-mgml-powder-concentrate-solution-infusion_en.pdf","publishedAt":"2011-09-08","page":23,"before":"famvir","paidUrl":"/ema-referrals?id=levact"},{"id":"clopidogrel-teva","name":"Clopidogrel Teva","date":"2011-09-08","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-clopidogrel-teva-and-associated-names-clopidogrel-75-mg-tablets_en.pdf","publishedAt":"2011-09-08","page":23,"before":"famvir","paidUrl":"/ema-referrals?id=clopidogrel-teva"},{"id":"clopidogrel-orion","name":"Clopidogrel Orion","date":"2011-09-08","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-clopidogrel-orion-and-associated-names-clopidogrel-75-mg-tablets_en.pdf","publishedAt":"2011-09-08","page":23,"before":"famvir","paidUrl":"/ema-referrals?id=clopidogrel-orion"},{"id":"arimidex","name":"Arimidex","date":"2011-07-27","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/arimidex-article-30-referral-assessment-report_en.pdf","publishedAt":"2011-07-27","page":23,"before":"famvir","paidUrl":"/ema-referrals?id=arimidex"},{"id":"isotretinoin-0","name":"Isotretinoin","date":"2011-07-15","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/isotretinoin-article-29-referral-assessment-report_en.pdf","publishedAt":"2011-07-15","page":23,"before":"famvir","paidUrl":"/ema-referrals?id=isotretinoin-0"},{"id":"myderison","name":"Myderison","date":"2011-06-16","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-referral-myderison-tablets-containing-tolperisone-hydrochloride-50-and-150-mg_en.pdf","publishedAt":"2011-06-16","page":23,"before":"famvir","paidUrl":"/ema-referrals?id=myderison"},{"id":"modified-released-oral-opioids","name":"Modified-released oral opioids","date":"2011-06-06","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/assessment-report-authorised-modified-release-oral-medicinal-products-who-level-iii-scale-management-pain-intense-sustained-pain-resistant-previous-medications-containing-morphine-oxycodone_en.pdf","publishedAt":"2011-06-06","page":23,"before":"famvir","paidUrl":"/ema-referrals?id=modified-released-oral-opioids"},{"id":"valproate","name":"Valproate","date":"2011-04-29","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/valproate-article-31-assessment-report_en.pdf","publishedAt":"2011-04-29","page":23,"before":"famvir","paidUrl":"/ema-referrals?id=valproate"},{"id":"ethirfin","name":"Ethirfin","date":"2011-04-29","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-ethirfin-and-associated-names-morphine-sulphate-prolonged-release-capsules-20-60-120-and-200-mg_en.pdf","publishedAt":"2011-04-29","page":23,"before":"famvir","paidUrl":"/ema-referrals?id=ethirfin"},{"id":"modafinil","name":"Modafinil","date":"2011-04-26","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/modafinil-h-31-1186-article-31-referral-assessment-report_en.pdf","publishedAt":"2011-04-26","page":24,"before":"daivobet","paidUrl":"/ema-referrals?id=modafinil"},{"id":"daivobet","name":"Daivobet","date":"2011-04-26","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-daivobet-and-associated-names-calcipotriolbetamethasone-gel-and-ointment-50-micrograms05-mg-g_en.pdf","publishedAt":"2011-04-26","page":23,"before":"famvir","paidUrl":"/ema-referrals?id=daivobet"},{"id":"dextropropoxyphene","name":"Dextropropoxyphene","date":"2011-04-07","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-withdrawal-marketing-authorisations-medicines-containing-dextropropoxyphene-re-examination_en.pdf","publishedAt":"2011-04-07","page":24,"before":"daivobet","paidUrl":"/ema-referrals?id=dextropropoxyphene"},{"id":"atacand","name":"Atacand","date":"2011-03-16","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-atacand-and-associated-names-candesartan-cilexetil-2-4-8-16-and-32-mg-tablets_en.pdf","publishedAt":"2011-03-16","page":24,"before":"daivobet","paidUrl":"/ema-referrals?id=atacand"},{"id":"pantoprazole-bluefish","name":"Pantoprazole Bluefish","date":"2011-03-09","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-referral-pantoprazole-bluefish-pantoprazole-20-and-40-mg-tablets_en.pdf","publishedAt":"2011-03-09","page":24,"before":"daivobet","paidUrl":"/ema-referrals?id=pantoprazole-bluefish"},{"id":"pantoprazole-olinka-emea-h-29-1170","name":"Pantoprazole Olinka (EMEA/H/A-29/1170)","date":"2011-03-08","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-referral-pantoprazole-olinka-pantoprazole-20-and-40-mg-tablets-emeaha-291170_en.pdf","publishedAt":"2011-03-08","page":24,"before":"daivobet","paidUrl":"/ema-referrals?id=pantoprazole-olinka-emea-h-29-1170"},{"id":"pantoprazole-olinka-emea-h-29-1169","name":"Pantoprazole Olinka (EMEA/H/A-29/1169)","date":"2011-03-08","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-referral-pantoprazole-olinka-pantoprazole-20-and-40-mg-tablets-emaha-291169_en.pdf","publishedAt":"2011-03-08","page":24,"before":"daivobet","paidUrl":"/ema-referrals?id=pantoprazole-olinka-emea-h-29-1169"},{"id":"gadolinium-containing-contrast-agents-0","name":"Gadolinium-containing contrast agents","date":"2010-12-06","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/gadolinium-h-31-1097-assessment-report_en.pdf","publishedAt":"2010-12-06","page":24,"before":"daivobet","paidUrl":"/ema-referrals?id=gadolinium-containing-contrast-agents-0"},{"id":"vascace","name":"Vascace","date":"2010-10-19","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-vascace-and-associated-names-cilazapril-05-1-25-and-5-mg-tablets_en.pdf","publishedAt":"2010-10-19","page":24,"before":"daivobet","paidUrl":"/ema-referrals?id=vascace"},{"id":"escitalopram","name":"Escitalopram","date":"2010-09-29","status":"CHMP opinion","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-generic-escitalopram-containing-medicines-tablets-containing-escitalopram-oxalate-5-10-15-and-20-mg_en.pdf","publishedAt":"2010-09-29","page":24,"before":"daivobet","paidUrl":"/ema-referrals?id=escitalopram"},{"id":"teicoplanin-hospira","name":"Teicoplanin Hospira","date":"2010-07-27","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-referral-teicoplanin-hospira-powder-and-solvent-injection-containing-200-or-400-mg-teicoplanin_en.pdf","publishedAt":"2010-07-27","page":24,"before":"daivobet","paidUrl":"/ema-referrals?id=teicoplanin-hospira"},{"id":"topamax","name":"Topamax","date":"2009-12-15","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-referral-topamax-and-associated-names-topiramate-tablets-and-capsules-final_en.pdf","publishedAt":"2009-12-15","page":25,"before":"teicoplanin-hospira","paidUrl":"/ema-referrals?id=topamax"},{"id":"meronem","name":"Meronem","date":"2009-12-12","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-referral-meronem-and-associated-names-meropenem-powder-solution-injection-or-infusion-500-mg-and-1-g-final_en.pdf","publishedAt":"2009-12-12","page":25,"before":"teicoplanin-hospira","paidUrl":"/ema-referrals?id=meronem"},{"id":"loratadine-sandoz-10","name":"Loratadine Sandoz 10","date":"2009-12-12","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-referral-loratadine-sandoz-10-loratadine-10-mg-tablets-final_en.pdf","publishedAt":"2009-12-12","page":25,"before":"teicoplanin-hospira","paidUrl":"/ema-referrals?id=loratadine-sandoz-10"},{"id":"rapinyl","name":"Rapinyl","date":"2009-09-25","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/opinion-following-article-294-referral-rapinyl-and-associated-names-international-non-proprietary-name-inn-fentanyl-citrate-background-information_en.pdf","publishedAt":"2009-09-25","page":25,"before":"teicoplanin-hospira","paidUrl":"/ema-referrals?id=rapinyl"},{"id":"prokanazol","name":"Prokanazol","date":"2009-08-06","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-referral-prokanazol-capsules-containing-itraconazole-100-mg_en.pdf","publishedAt":"2009-08-06","page":25,"before":"teicoplanin-hospira","paidUrl":"/ema-referrals?id=prokanazol"},{"id":"fentrix","name":"Fentrix","date":"2009-06-25","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-referral-fentrix-and-associated-names-25-50-70-and-100-microgramhour-fentanyl-transdermal-patch_en.pdf","publishedAt":"2009-06-25","page":25,"before":"teicoplanin-hospira","paidUrl":"/ema-referrals?id=fentrix"},{"id":"budesonide-sandoz","name":"Budesonide Sandoz","date":"2009-06-25","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-referral-budesonide-sandoz-nasal-suspension-32-or-64-microgram-spray_en.pdf","publishedAt":"2009-06-25","page":25,"before":"teicoplanin-hospira","paidUrl":"/ema-referrals?id=budesonide-sandoz"},{"id":"diovan-comp","name":"Diovan Comp","date":"2009-06-11","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-referral-diovan-comp-and-associated-names-tablets-containing-valsartan-80-160-or-320-mg-and-hydrochlorothiazide-125-or-25-mg_en.pdf","publishedAt":"2009-06-11","page":25,"before":"teicoplanin-hospira","paidUrl":"/ema-referrals?id=diovan-comp"},{"id":"tritazide","name":"Tritazide","date":"2009-04-14","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-referral-tritazide-tablets-containing-ramipril-and-hydrochlorothiazide-25125-mg-5125-mg-525-mg_en.pdf","publishedAt":"2009-04-14","page":25,"before":"teicoplanin-hospira","paidUrl":"/ema-referrals?id=tritazide"},{"id":"bleomycin","name":"Bleomycin","date":"2009-03-31","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-referral-bleomycin-powder-solution-injection-15-uvial-pharmachemie-bv_en.pdf","publishedAt":"2009-03-31","page":25,"before":"teicoplanin-hospira","paidUrl":"/ema-referrals?id=bleomycin"},{"id":"sanohex","name":"Sanohex","date":"2009-03-30","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-referral-sanohex-salbutamol-metered-dose-aerosol-inhaler-100-mg-dose_en.pdf","publishedAt":"2009-03-30","page":26,"before":"bleomycin","paidUrl":"/ema-referrals?id=sanohex"},{"id":"diovan-0","name":"Diovan","date":"2009-03-13","status":"European Commission final decision","sourceUrl":"https://www.ema.europa.eu/en/documents/referral/questions-and-answers-referral-diovan-film-coated-tablets-and-hard-capsules-containing-valsartan-40-80-160-or-320-mg_en.pdf","publishedAt":"2009-03-13","page":26,"before":"bleomycin","paidUrl":"/ema-referrals?id=diovan-0"}],"schema":{"fields":["id","name","date","status","sourceUrl"]},"sources":{"index":"https://www.ema.europa.eu/en/documents/report/referrals-output-json-report_en.json","pdfHost":"https://www.ema.europa.eu/en/documents/referral/","pageHost":"https://www.ema.europa.eu/"},"search":null,"before":null,"date":null,"openapi":"https://ticks.bnm.farm/openapi.json","wellKnown":"https://ticks.bnm.farm/.well-known/x402","llmsTxt":"https://ticks.bnm.farm/llms.txt","mcp":"https://ticks.bnm.farm/mcp","sample":"https://ticks.bnm.farm/sample","firmCheck":"https://ticks.bnm.farm/firm-check"}